| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥61.5B | ¥63.2B | -2.8% |
| Operating Income | ¥0.8B | ¥7.7B | -89.8% |
| Profit Before Tax | ¥0.8B | ¥7.5B | -88.9% |
| Net Income | ¥0.4B | ¥2.3B | -84.4% |
| ROE | 1.2% | 7.7% | - |
FY2026 Q3 results show revenue of 61.5B yen (YoY -2.8%) with operating income declining sharply to 0.8B yen (YoY -89.8%). Net income fell to 0.4B yen (YoY -84.4%) from 2.3B yen in the prior year period. The dramatic profit contraction occurred despite relatively stable revenue, as operating margin compressed to 1.3% from 12.2% YoY. Gross profit margin held at 36.1%, but SG&A expenses of 21.6B yen consumed nearly all gross profit, resulting in minimal operating leverage. ROE declined to 1.2% from higher historical levels, driven primarily by net margin compression to 0.6%. The effective tax rate of 56.7% further pressured bottom-line results. Financial position remains stable with equity ratio of 44.3% and total assets of 69.1B yen, though cash declined 33.6% YoY to 18.4B yen. The company forecasts full-year revenue of 83.4B yen with operating income of 1.9B yen, implying significant H2 recovery required to meet guidance.
Revenue declined 2.8% YoY to 61.5B yen, with the Dispensing Pharmacy and Related segment contributing 51.8B yen (approximately 84% of total revenue), Internet-Related business generating 8.0B yen, and Telecommunications 1.6B yen. The revenue decline was relatively modest, but profit performance deteriorated substantially. Operating income collapsed 89.8% from 7.7B yen to 0.8B yen, primarily driven by a significant non-recurring gain in the prior year period. The prior year Q3 included a gain on sale of affiliated company stock of 512.9M yen recorded in "Other Revenue," which did not recur in the current period. Excluding this one-time item, prior year core operating profit would have been approximately 2.6B yen, indicating current period core operations still declined roughly 70% year-over-year. SG&A expenses increased to 21.6B yen from 21.2B yen despite lower revenue, resulting in SG&A ratio expansion to 35.1% from 33.5%. This operating deleverage reflects either fixed cost burden against declining volume or integration costs from the acquisition of Security Agent by subsidiary Sophia Research Institute during Q3. The gap between operating income (0.8B yen) and ordinary income is minimal, with net financial costs of 17.6M yen offset by financial income of 22.3M yen. However, the gap between profit before tax (0.8B yen) and net income (0.4B yen) represents an effective tax rate of 56.7%, significantly elevated compared to standard corporate tax rates and suggesting temporary differences or non-deductible expenses. This represents a revenue down/profit down pattern, with profit decline substantially exceeding revenue decline due to operating deleverage and non-recurring factors.
The Dispensing Pharmacy and Related segment is the core business, generating 5,179M yen in external revenue (84.3% of total) with segment profit of 402.3M yen, representing a segment margin of 7.8%. This segment experienced revenue decline of 0.6% YoY from 5,208M yen, with segment profit falling 14.8% from 472.3M yen, indicating margin compression within the core pharmacy operations. The Internet-Related segment recorded external revenue of 804M yen with segment profit of 38.3M yen (4.7% margin), down substantially from prior year revenue of 1,000M yen and profit of 64.5M yen. This 19.6% revenue decline and 40.6% profit decline reflects challenging market conditions in system development and engineering services. The consolidation of Security Agent as a subsidiary during Q3 did not offset organic weakness in this segment. The Telecommunications segment generated external revenue of 162.2M yen with segment profit of 21.8M yen (13.4% margin), improving significantly from prior year revenue of 102.8M yen and segment loss of 5.2M yen. This 57.8% revenue growth and return to profitability represents the strongest performance across segments, suggesting MVNO business model improvements. Corporate costs and eliminations resulted in a negative adjustment of 374.1M yen to consolidated operating income, substantially higher than the prior year adjustment of negative 237.1M yen (excluding the 512.9M yen gain). This 58% increase in unallocated costs indicates elevated holding company expenses or integration costs not assigned to operating segments.
[Profitability] ROE of 1.2% declined sharply from prior year levels, operating margin compressed to 1.3% from 12.2% YoY, and net margin fell to 0.6% reflecting both operational challenges and elevated tax burden. Gross margin maintained at 36.1% demonstrates stable pricing at the sales level, but operating leverage deteriorated significantly. [Cash Quality] Cash and equivalents of 18.4B yen provide coverage of 4.1x against short-term borrowings of 4.5B yen, though total cash declined 9.0B yen or 33.6% from prior year. Receivables turnover stands at approximately 73 days (calculated as 12.3B yen receivables / 61.5B yen revenue × 275 days), indicating moderate collection efficiency. [Investment Efficiency] Asset turnover ratio of 0.89x (revenue 61.5B yen / average assets approximately 69B yen) exceeds industry median of 0.67x, suggesting relatively efficient asset utilization despite profit challenges. Inventory of 5.6B yen represents approximately 33 days of cost of sales, consistent with pharmacy operations requiring medication stock. [Financial Health] Equity ratio of 44.3% remains solid, current assets of 37.8B yen against current liabilities (inferred from balance sheet structure) indicate adequate liquidity coverage, and debt-to-equity ratio of 0.35x (calculated as interest-bearing debt of 10.7B yen / equity 30.6B yen) represents conservative leverage. However, goodwill of 18.1B yen represents 59% of total equity, presenting potential impairment risk if segment performance does not recover.
Cash and deposits decreased 9.0B yen YoY to 18.4B yen, representing a 33.6% decline that warrants attention given the magnitude of reduction. This substantial cash outflow occurred despite positive net income of 0.4B yen for the period, suggesting significant uses of cash beyond operating losses. Working capital movements show receivables increasing to 12.3B yen while inventories remained stable at 5.6B yen, indicating potential collection cycle extension that consumed cash. The decline in both short-term borrowings by 3.2B yen (to 4.5B yen) and long-term borrowings by 2.7B yen (to 6.2B yen) totaling 5.9B yen of debt reduction represents a major financing outflow that explains a substantial portion of the cash decline. Lease liabilities totaling 7.0B yen (current 1.2B yen plus non-current 5.8B yen) reflect right-of-use assets of 6.0B yen, indicating pharmacy location leases as expected for the retail pharmacy business model. The combination of debt repayment and working capital consumption against minimal operating profit generation resulted in the significant cash drawdown. Trade payables increased modestly to 17.8B yen, providing some working capital relief but insufficient to offset other cash uses. With current cash coverage of 4.1x against short-term debt and significant lease obligations, near-term liquidity appears adequate though the cash consumption trend requires monitoring and reversal for sustainable operations.
Operating income of 0.8B yen compares to ordinary income of 0.8B yen, with minimal non-operating impact as financial income of 22.3M yen approximately offset financial costs of 17.6M yen. The prior year period included a significant non-recurring gain of 512.9M yen from sale of affiliated company stock recorded in "Other Revenue," which inflated prior year operating profit to 7.7B yen from a core level of approximately 2.6B yen. Excluding this one-time item, current period core operations still declined approximately 70%, indicating genuine operational challenges beyond non-recurring factors. The current period shows minimal other revenue of 15.6M yen compared to 531.1M yen in prior year, confirming absence of significant one-time gains. Non-operating income represents less than 1% of revenue, consisting primarily of ordinary course financial items without material equity method gains or extraordinary components. The substantial gap between profit before tax (0.8B yen) and net income (0.4B yen) reflects an effective tax rate of 56.7%, significantly elevated compared to Japan's standard corporate tax rate of approximately 30%. This elevated tax burden may reflect non-deductible expenses, temporary differences, or subsidiary loss limitations, and represents a earnings quality concern requiring clarification. Without cash flow statement data, the relationship between net income and operating cash flow cannot be directly assessed, though the significant cash decline of 9.0B yen against minimal net income of 0.4B yen suggests operating cash generation is challenged and cash outflows relate primarily to debt repayment and working capital requirements.
The company maintains full-year guidance of revenue 83.4B yen, operating income 1.9B yen, and net income 0.9B yen. Against nine-month actual results of revenue 61.5B yen (73.7% progress rate), operating income 0.8B yen (42.1% progress rate), and net income 0.4B yen (40.4% progress rate), the guidance implies significant Q4 acceleration. Q4 implied performance would require revenue of approximately 21.9B yen (representing 26.3% of full-year revenue in a single quarter), operating income of 1.1B yen, and net income of 0.5B yen. The Q4 operating income target of 1.1B yen would exceed the cumulative nine-month total of 0.8B yen, requiring substantial margin improvement or one-time gains to achieve. Historical quarterly patterns show Q3 typically represents approximately 75% of annual progress, meaning current 42% operating income progress rate reflects a significant 33 percentage point shortfall. The company has not announced a guidance revision despite this substantial gap, suggesting management confidence in Q4 recovery driven by seasonality, cost initiatives, or potential transactions. Operating income guidance of 1.9B yen represents 45.2% decline from prior year's 3.5B yen (adjusted for non-recurring gains), indicating management acknowledges structural profit pressure. Net income guidance of 0.9B yen implies approximately 2.4% decline from prior year, substantially better than operating income trend, suggesting expectation of lower effective tax rate in Q4. Investors should focus on Q4 disclosure of specific recovery drivers, as achieving guidance requires operating margin expansion to approximately 5% in Q4 compared to 1.3% YTD average.
The company has announced zero dividend for the full fiscal year, with dividend forecast of 0.00 yen per share. This represents elimination of prior year dividend payments, reflecting management's prioritization of cash preservation given operating profit pressure and cash balance decline. With full-year net income guidance of 0.9B yen and zero dividend, the payout ratio is 0%, indicating complete retention of earnings for operational needs or balance sheet strengthening. No share buyback programs have been disclosed for the current fiscal year. The elimination of dividends despite positive net income forecast suggests management assessment that cash resources should be directed toward working capital management, debt reduction, or business investment rather than shareholder distributions. Total return ratio (dividends plus buybacks divided by net income) stands at 0% for the current forecast period. The dividend policy shift from payment to suspension represents a material change that shareholders should evaluate in context of the 33.6% cash balance decline and need to fund ongoing operations and potential growth initiatives.
Operating margin sustainability represents the primary risk, as 1.3% operating margin for the nine-month period provides minimal buffer against revenue volatility or cost increases, with SG&A expenses of 35.1% of revenue requiring structural reduction to restore acceptable profitability levels. The Dispensing Pharmacy segment generates 84% of revenue with segment margin of 7.8%, exposing the company to regulatory changes in drug reimbursement rates, competitive pressure from larger pharmacy chains, and demographic shifts in prescription volume that could further compress margins. Goodwill of 18.1B yen representing 59% of total equity creates impairment risk if acquired businesses fail to meet performance targets, particularly given current operating profit of only 0.8B yen provides limited cushion to absorb potential write-downs, and any material goodwill impairment would significantly reduce equity and potentially breach lending covenants. Cash generation deterioration evidenced by 9.0B yen or 33.6% decline in cash balance over nine months, combined with working capital pressure from 73-day receivables collection cycle, creates liquidity risk if operating performance does not improve, particularly as the company maintains 7.0B yen of lease obligations and 10.7B yen of interest-bearing debt requiring ongoing service. Tax burden uncertainty with effective tax rate of 56.7% substantially above normal corporate rates indicates potential structural tax disadvantages or subsidiary loss utilization limitations that could persist and pressure net income even if operating performance recovers. Integration execution risk from acquisition of Security Agent by Sophia Research Institute subsidiary during Q3, as integration costs appear to have elevated corporate expenses by 374.1M yen in segment adjustments, and failure to achieve synergies would further pressure already weak Internet-Related segment performance.
[Industry Position] (Reference - Proprietary Analysis) The company's operating margin of 1.3% falls substantially below the IT and Telecommunications industry median of 8.2% (IQR: 3.6%-18.0%), indicating significant underperformance in operational efficiency relative to peers. Net profit margin of 0.6% similarly lags the industry median of 6.0% (IQR: 2.2%-12.7%), reflecting both operating challenges and elevated tax burden. ROE of 1.2% compares unfavorably to industry median of 8.3% (IQR: 3.6%-13.1%), positioning the company in the bottom quartile of peer profitability. The equity ratio of 44.3% sits below industry median of 59.2% (IQR: 42.5%-72.7%), though remains within acceptable range, indicating moderately higher financial leverage than typical industry participants. Asset turnover of 0.89x exceeds industry median of 0.67x (IQR: 0.49-0.93), representing relative strength in asset utilization efficiency despite profit challenges. Revenue decline of 2.8% contrasts negatively with industry median growth of 10.4% (IQR: -1.2% to 19.6%), placing the company in the lower half of growth performance. Receivables turnover of approximately 73 days aligns closely with industry median of 61 days (IQR: 46-83 days), suggesting collection efficiency is consistent with sector norms and not a relative weakness. The company's financial leverage of 2.26x exceeds industry median of 1.66x (IQR: 1.36-2.32), though remains within reasonable range given the equity ratio position. Overall industry positioning indicates the company faces primarily operational and profitability challenges rather than structural balance sheet or efficiency disadvantages, with margin improvement representing the critical priority to align with peer performance levels.
(Industry: IT and Telecommunications, Comparison: 2025-Q3 median and interquartile range across approximately 90-104 peer companies, Source: Proprietary analysis)
The sharp operating margin contraction to 1.3% from historical levels represents the most significant characteristic observed in the earnings data, driven by operating deleverage as SG&A expenses remained elevated despite revenue decline, with the prior year benefit of 512.9M yen non-recurring gain masking underlying operational challenges that became fully visible in the current period. Achievement of full-year guidance requires Q4 operating income of 1.1B yen exceeding the cumulative nine-month total of 0.8B yen, representing a critical inflection point that will determine whether current weakness is temporary or structural, with specific disclosure of Q4 recovery drivers essential for credibility assessment. The 33.6% decline in cash balance to 18.4B yen combined with 73-day receivables cycle indicates working capital management challenges that consumed liquidity despite debt reduction of 5.9B yen, suggesting operational cash generation was negative and highlighting the importance of monitoring Q4 cash flow statement when disclosed. Goodwill of 18.1B yen at 59% of equity creates asymmetric downside risk given minimal operating profit of 0.8B yen provides limited coverage for potential impairment, with segment performance recovery particularly in Internet-Related and Dispensing Pharmacy operations necessary to support carrying values. The elimination of dividends despite positive earnings guidance signals management prioritization of balance sheet preservation and indicates confidence in guidance achievement remains qualified by need to retain all available cash, with restoration of shareholder returns likely dependent on sustained margin recovery beyond the current fiscal year.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.